13th May 2019 10:44
LONDON (Alliance News) - Polarean Imaging PLC on Monday said that it is progressing on its phase III clinical trials and plans to add an extra site in its lung resection pathway trial to improve the rate of enrollment.
The company is carrying out two trials at Duke University and at the University of Virginia to demonstrate non-inferiority of its drug-device combination for the evaluation of pulmonary ventilation.
Enrollment for the trials has now passed 80%, with 39 of 48 patients, in the lung transplant pathway and 50%, 16 of 32 patients, in the lung resection pathway.
"To improve the rate of enrollment for the lung resection pathway in order to align the pathway completion dates and because neither site should enroll more than 65% of patients in a pathway, the company plans to add a third trial site," Polarean explained.
The additional site will be the University of Cincinnati, which is already a key clinical collaborator.
Chief Executive Officer Richard Hullihen said: "We are satisfied with the progress of our clinical trials to date. We are pleased to be adding an additional trial site at University of Cincinnati to improve the enrollment process for the lung resection pathway, thereby extending our collaboration with UC."
Polarean shares were untraded at 16.12 pence each on Monday.
Related Shares:
polarean